C.R. Bard Inc. (NYSE:BCR) has been given a consensus rating of “Hold” by the nineteen brokerages that are presently covering the stock. Thirteen equities research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $232.46.

A number of equities research analysts have weighed in on BCR shares. JPMorgan Chase & Co. lifted their target price on C.R. Bard from $214.00 to $225.00 and gave the stock a “neutral” rating in a report on Wednesday, July 27th. Morgan Stanley reiterated a “hold” rating and issued a $240.00 target price on shares of C.R. Bard in a report on Thursday, July 28th. Citigroup Inc. lifted their target price on C.R. Bard from $241.00 to $265.00 and gave the stock a “buy” rating in a report on Wednesday, July 27th. Deutsche Bank AG lifted their target price on C.R. Bard from $234.00 to $240.00 and gave the stock a “hold” rating in a report on Wednesday, July 27th. Finally, Evercore ISI started coverage on C.R. Bard in a report on Thursday, September 15th. They issued a “buy” rating and a $235.00 target price for the company.

In other C.R. Bard news, VP Betty D. Larson sold 4,032 shares of the business’s stock in a transaction on Monday, September 19th. The stock was sold at an average price of $225.33, for a total value of $908,530.56. Following the transaction, the vice president now owns 10,298 shares of the company’s stock, valued at $2,320,448.34. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Chairman Timothy M. Ring sold 110,000 shares of the business’s stock in a transaction on Monday, September 26th. The stock was sold at an average price of $228.96, for a total value of $25,185,600.00. Following the completion of the transaction, the chairman now directly owns 96,030 shares in the company, valued at approximately $21,987,028.80. The disclosure for this sale can be found here. 0.97% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. IFP Advisors Inc boosted its position in shares of C.R. Bard by 8.5% in the first quarter. IFP Advisors Inc now owns 675 shares of the company’s stock worth $137,000 after buying an additional 53 shares in the last quarter. Pacad Investment Ltd. purchased a new position in shares of C.R. Bard during the first quarter worth approximately $521,000. Franklin Resources Inc. boosted its position in shares of C.R. Bard by 197.6% in the first quarter. Franklin Resources Inc. now owns 140,825 shares of the company’s stock worth $28,541,000 after buying an additional 93,504 shares in the last quarter. BlackRock Group LTD boosted its position in shares of C.R. Bard by 15.0% in the first quarter. BlackRock Group LTD now owns 893,218 shares of the company’s stock worth $181,028,000 after buying an additional 116,835 shares in the last quarter. Finally, BlackRock Fund Advisors boosted its position in shares of C.R. Bard by 8.5% in the first quarter. BlackRock Fund Advisors now owns 1,886,656 shares of the company’s stock worth $382,369,000 after buying an additional 147,571 shares in the last quarter. 87.90% of the stock is currently owned by institutional investors and hedge funds.

Shares of C.R. Bard (NYSE:BCR) opened at 222.97 on Wednesday. The stock has a 50 day moving average price of $221.85 and a 200 day moving average price of $220.14. The firm has a market cap of $16.38 billion, a P/E ratio of 51.85 and a beta of 0.50. C.R. Bard has a 12-month low of $172.21 and a 12-month high of $239.43.

C.R. Bard (NYSE:BCR) last posted its quarterly earnings data on Tuesday, July 26th. The company reported $2.54 EPS for the quarter, topping the Zacks’ consensus estimate of $2.47 by $0.07. The company had revenue of $931.50 million for the quarter, compared to analyst estimates of $915.22 million. C.R. Bard had a return on equity of 48.43% and a net margin of 9.20%. The firm’s quarterly revenue was up 8.3% on a year-over-year basis. During the same period in the previous year, the firm earned $2.27 earnings per share. On average, equities analysts expect that C.R. Bard will post $10.17 earnings per share for the current year.

About C.R. Bard

C. R. Bard, Inc (Bard) and its subsidiaries are engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities.

5 Day Chart for NYSE:BCR

Receive News & Stock Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related stocks with our FREE daily email newsletter.